Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK statisticians and trialists reach out to the clinical trial community in an awareness-raising paper published this week as a first step in changing practice. They promote the use of adaptive designs in early-phase clinical trials to improve trial efficiency, which will benefit patients.

Human clinical trials should be based on the best possible evidence. However, changing the design used in early-phase trials has proved challenging, even when newer methods increase the chance that the trial will get the correct answer. The NIHR Statisticians Research Group on Early Phase Clinical Trials, which includes CSM statisticians, is on a mission to help clinical trialists to underpin their phase I trials with best-practice designs. They target clinicians, nurses and statisticians in an open-access motivational awareness-raising paper published in the British Journal of Cancer this week.    

The first time a promising new medical treatment leaves the laboratory and is tested in a person is in a phase I dose-finding trial. These trials give a series of human participants different doses of the drug to find out which doses are not too toxic for humans. 

Phase I trials typically use rules set before the trial starts to decide what dose each participant gets. However, 20 years of statistics research has overwhelmingly shown that it is better to use mathematical models that decide each participant’s dose using the information gathered in the trial up until that participant. Although pharmaceutical companies have switched to using these models, academic trials still tend to use rules. Only 6.7% of all dose-finding trials use best-practice model-based designs!

CSM’s Sharon Love is a member of the NIHR Statisticians Research Group and a co-author on the motivational paper. She says, “This is the start of a concerted effort by UK statisticians and trialists using these designs to make them accessible to all. This first paper explains the benefits of using model-based designs and how to overcome barriers to using them. In collaboration with the MRC Network of Hubs for Trials Methodology Research's Adaptive Designs Working Group, we have submitted a second paper that will take readers through each step of the design of model-based design using non-statistical language.”     

The NIHR Statisticians Research Group plans to offer courses in 2018 to train trialists in using model-based designs for phase I trials. As these best-practice methods are used by the trials research community, the Group plans to conduct methodology research on the challenges that trialists discover when using these methods.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.